Lexaria Bioscience Missed Consensus Estimates

Lexaria Bioscience (LEXX) reported a loss of $0.08 per share on revenue of $0.00 million for the fiscal third quarter ended May 2026. The consensus estimate was a loss of $0.06 per share on revenue of $1.40 million. The company missed consensus estimates by 33.33% while revenue fell 100.00% compared to the same quarter a year ago.

Lexaria Bioscience Corp. provides drug delivery platforms. Its patented DehydraTECH(TM) drug delivery technology changes the way Active Pharmaceutical Ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. Lexaria Bioscience Corp. is based in Kelowna, Canada.